Immuneering Corp — Director's Dealing 2023

Jun 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2023-06-13

Reporting Person: Morales Mallory (VICE PRESIDENT, FINANCE)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-13	Stock Option	$9.55	A	15000	Acquired	2033-06-13	Class A Common Stock (15000)	Direct

Footnotes

F1: The option vests and becomes exercisable (subject to continued service to the Issuer through the applicable vesting date) in forty-eight (48) substantially equal monthly installments following the vesting commencement date of July 1, 2023, and will be fully vested and exercisable on July 1, 2027.